HPV Vaccination: Too Soon for 2 Doses?

• Autores: Jessica A. Kahn
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 309, Nº. 17, 2013 (Ejemplar dedicado a: Child Health), págs. 1832-1834
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Cervical cancer is the second most common cancer among women globally, according to age-standardized incidence rates.1 Approximately 530 000 women are diagnosed with cervical cancer and 275 000 die of the disease every year; 88% of deaths occur in developing regions of the world.1 Human papillomavirus (HPV) infection is a well-established cause of cervical cancer as well as other anogenital and oropharyngeal cancers; therefore, prophylactic HPV vaccines have the potential to substantially reduce the incidence of cervical cancer and other HPV-associated diseases.2 Three-dose schedules of the bivalent vaccine (HPV-16 and -18) and the quadrivalent vaccine (HPV-6, -11, -16, and -18) have been shown to be highly efficacious in preventing persistent infection with HPV-16 and -18, which cause approximately 70% of cervical cancers, as well as precancerous lesions associated with these types.3- 5 The quadrivalent vaccine has also been shown to prevent anogenital warts associated with HPV-6 and -11.3,5